# Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL

> **NCT05702853** · PHASE1,PHASE2 · RECRUITING · sponsor: **Medical University of South Carolina** · enrollment: 27 (estimated)

## Conditions studied

- B-cell Non Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Cyclophosphamide injection
- **DRUG:** Fludarabine Injection
- **BIOLOGICAL:** CD19-CD34t metabolically programmed CAR transduced T-cells

## Key facts

- **NCT ID:** NCT05702853
- **Lead sponsor:** Medical University of South Carolina
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-06
- **Primary completion:** 2026-11-06
- **Final completion:** 2026-12-30
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05702853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05702853, "Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05702853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*